专利号:US-10364220-B2 优先权日:2012-12-21 标题:Synthesis of succinimides and quaternary ammonium ions for use in making molecular sieves 发明人:SCHMITT KIRK D; ZUSHMA STEPHEN; BURTON ALLEN W 权利人:EXXONMOBIL CHEMICAL PATENTS INC 摘要:The present invention relates to the synthesis of succinimides, in particular to a method for the synthesis of a succinimide compound, comprising the step of reacting an alkyne, with carbon monoxide and ammonia or an amine, in the presence of an iron catalyst, wherein the reaction is carried out in an amine liquid phase and/or in the absence of an ether solvent. The succinimides may be reduced to quaternary ammonium cations which may be used as structure directing agents in the synthesis of molecular sieves.
专利号:US-4857659-A 优先权日:1986-04-28 标 题:Stereoselective synthesis of leukotriene antagonists 发明人:FRENETTE RICHARD; GAUTHIER JACQUES-YVES; YOUNG ROBERT N; ZAMBONI ROBERT; KAKUSHIMA MASATOSHI; VERHOEVEN THOMAS R 权利人:MERCK FROSST CANADA INC 摘要:The present invention relates to a stereo-selective synthesis of leukotriene antagonists. More particularly, this invention relates to the stereo-selective synthesis of (βS,γR) and (βR,γS)-4-((3-(4-acetyl-3-hydroxy-2-propyl(phenoxy)propyl)-thio-γ-hydroxy-β-methylbenzenebutanoic acid, and related compounds. These compounds are useful therapeutic agents for treating allergic conditions, asthma, cardiovascular, disorders, inflammation and pain in mammals, especially humans. The compounds are also useful for inducing cytoprotection in mammals, especially humans.
专利号:US-2024207831-A1 优先权日:2022-12-08 标 题 :Molecular Sieve CIT-16P, Its Synthesis, Transformation and Use 发明人:KANG JONG HUN; ALSHAFEI FAISAL H; DAVIS MARK E 权利人:CALIFORNIA INST OF TECHN 摘要:The disclosure provides a novel silicoaluminophosphate molecular sieve, referred to as CIT-16P, that comprises a silicoaluminophosphate framework with an occluded OSDA that is DiQ-C 4 or DiQ-C 3 . The synthesis of CIT-16P, its conversion to SAPO-17, and the use of the so-derived SAPO-17 in the MTO reaction are also disclosed.
专利号:US-9085518-B2 优先权日:2011-10-14 标题 :Method for the synthesis of 18F-labelled molecules 发明人:NAIRNE ROBERT JAMES DOMETT; BHALLA RAJIV; KHAN IMTIAZ; BROWN JANE; WILSON ANTHONY; BLACK ANDRES 权利人:GE HEALTHCARE LTD 摘要:The present invention provides a method for the synthesis of 18F-labelled biomolecules, which is amenable to automation. The present invention also provides a cassette for automating the method of the invention. The method of the present invention provides numerous advantages over the prior art methods. One less purification step is required as compared with known methods. Also, in a preferred embodiment, one less reagent is required as a particular reagent is employed in two different steps. The chemistry process is thereby simplified, the cost of goods is reduced and the burden of validation and documentation of reagents required for GMP clinical production is minimized.
专利号:US-9879043-B1 优先权日:2013-06-06 标 题:Synthesis of non-natural cofactor analogs of S-adenosyl-L-methionine using methionine adenosyltransferase 发明人:THORSON JON; HUBER TYLER; ZHANG JIANJUN; Singh Shanteri 权利人:UNIV KENTUCKY RES FOUND 摘要:The present disclosure relates to the synthesis of non-natural analogs of S-adenosyl-L-methionine (SAM) and/or of Se-adenosyl-L-methionine (SeAM) by reacting a methionine analog and adenosine triphosphate (ATP) in the presence of at least one methionine adenosyltransferase (MAT), and to use thereof with downstream SAM and/or SeAM utilizing enzymes. The non-natural analogs of SAM and/or SeAM have the general formula: n nwhere X is S or Se, and R 1 is an alkyl group.
专利号:US-9125954-B2 优先权日:2011-10-14 标 题 :Method for the synthesis of 18F-labelled biomolecules 发明人:BHALLA RAJIV; WILSON ANTHONY; KHAN IMTIAZ; BROWN JANNE 权利人:GE HEALTHCARE LTD 摘要:The present invention provides a method for the synthesis of 18 F-labelled biomolecules, which is amenable to automation. The present invention also provides a cassette for automating the method of the invention. The method of the present invention provides numerous advantages over the prior art methods. One less purification step is required as compared with known methods. Also, one less reagent is required as a particular reagent is employed in two different steps. The chemistry process is thereby simplified, the cost of goods is reduced and the burden of validation and documentation of reagents required for GMP clinical production is minimized.
参考文献:10.3797/scipharm.1012-17 摘要:Bielenica A, Kossakowski J, Struga M, Dybała I, Loddo R, Ibba C, La Colla P. Synthesis and Biological Evaluation of New 3-Phenyl-1-[(4-arylpiperazin-1-yl)alkyl]-piperidine-2,6-diones. Sci Pharm. 2011 Apr;79(2):225–38.